drugset / Trial / NCT01451749

Efficacy and Safety Study of Shenwu Capsule

NCT01451749

Phase 3 Completed 324 enrolled North China Pharmaceutical Group Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this phase III study is to further evaluate the effects of shenwu capsule, a traditional Chinese herbal medicine, on cognition, function and memory in patients with amnestic mild cognitive impairment (MCI) who are at greater risk for developing Alzheimer's disease, in a 6-month supervised protocol of a traditional Chinese herbal medicine. The results of this study may provide support for a relatively simple and inexpensive treatment strategy with herbal therapy that specifically targets individuals with the mild cognitive impairment that directly influence risk of developing dementia for older adults.

Timeline

Start
2008-09
Primary completion
2009-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Donepezil Small molecule 5 mg
Subject Shenwu Capsule Traditional medicine (herbal / TCM) 451 mg